Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0126


Decision-making treatment for early breast cancer and future perspectives.

Dimosthenis Ziogas, M.D.

Affiliation: Dimosthenis Ziogas M.D., Department of Surgery, University of Ioannina , School of Medicine , 45110 Ioannina , Greece .



Currently decision-making for the treatment of women with early, node-negative breast cancer is based on age, tumor size, grade, estrogen receptor (ER) status and HER2 status. However, about 30% of these patients receiving an unnecessary systemic chemotherapy and another substantial proportion an inadequate treatment with intrinsic or acquired resistance. More recently, to improve these decisions the multigene assays 21-gene (Oncotype DX) and 70-gene signature (MammaPrint) and the isolated tumor cells (ITCs) in sentinel lymph node(s) are proposed.

In this review article, the advantages and limitations of these new markers are discussed and considering a balance of risks and benefits a treatment approach is suggested. Moreover, the potential of molecular networks research to develop novel biomarkers for improving a tailored breast cancer treatment is also described.




You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 6 March 2010